Ausgabe 1/2019
Inhalt (26 Artikel)
Atypical ductal hyperplasia in men with gynecomastia: what is their breast cancer risk?
Suzanne B. Coopey, Kinyas Kartal, Clara Li, Adam Yala, Regina Barzilay, Heather R. Faulkner, Tari A. King, Francisco Acevedo, Judy E. Garber, Anthony J. Guidi, Kevin S. Hughes
The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea
Hope S. Rugo, Jack A. Di Palma, Debu Tripathy, Richard Bryce, Susan Moran, Elizabeth Olek, Linda Bosserman
Tamoxifen and pregnancy: an absolute contraindication?
T. N. Schuurman, P. O. Witteveen, E. van der Wall, J. L. M. Passier, A. D. R. Huitema, F. Amant, C. A. R. Lok
The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer
Rokaya El-Ansari, Madeleine L. Craze, Lutfi Alfarsi, Daniele Soria, Maria Diez-Rodriguez, Christopher C. Nolan, Ian O. Ellis, Emad A. Rakha, Andrew R. Green
S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability of cancer stem cells
Elena Strekalova, Dmitry Malin, Erin M. M. Weisenhorn, Jason D. Russell, Dominik Hoelper, Aayushi Jain, Joshua J. Coon, Peter W. Lewis, Vincent L. Cryns
Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases
Zhi-Hua Liu, Kun Wang, Dan-Yi Lin, Jie Xu, Jie Chen, Xiao-Yu Long, Yan Ge, Xin-Lan Luo, Ke-Ping Zhang, Yan-Hui Liu, Fang-Ping Xu
An eight-lncRNA signature predicts survival of breast cancer patients: a comprehensive study based on weighted gene co-expression network analysis and competing endogenous RNA network
Min Sun, Di Wu, Ke Zhou, Heng Li, Xingrui Gong, Qiong Wei, Mengyu Du, Peijie Lei, Jin Zha, Hongrui Zhu, Xinsheng Gu, Dong Huang
ID2 and GJB2 promote early-stage breast cancer progression by regulating cancer stemness
Yin Liu, Puspa R. Pandey, Sambad Sharma, Fei Xing, Kerui Wu, Amar Chittiboyina, Shih-Ying Wu, Abhishek Tyagi, Kounosuke Watabe
Revealing clonality and subclonality of driver genes for clinical survival benefits in breast cancer
Yujia Lan, Erjie Zhao, Shangyi Luo, Yun Xiao, Xia Li, Shujun Cheng
Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers
Constantinos Savva, Karen De Souza, Reem Ali, Emad A. Rakha, Andrew R. Green, Srinivasan Madhusudan
Prognostic effects of abnormal DNA damage response protein expression in breast cancer
Koung Jin Suh, Han Suk Ryu, Kyung-Hun Lee, Hyojin Kim, Ahrum Min, Tae-Yong Kim, Yaewon Yang, Han-Byoel Lee, Hyeong-Gon Moon, Sae-Won Han, Do-Youn Oh, Wonshik Han, In Ae Park, Dong-Young Noh, Seock-Ah Im
Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer
Nicola J. Camp, Michael J. Madsen, Jesús Herranz, Álvaro Rodríguez-Lescure, Amparo Ruiz, Miguel Martín, Philip S. Bernard
Differences between screen-detected and interval breast cancers among BRCA mutation carriers
Melissa Pilewskie, Emily C. Zabor, Elizabeth Gilbert, Michelle Stempel, Oriana Petruolo, Debra Mangino, Mark Robson, Maxine S. Jochelson
Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)—PathIES
Zsolt Szijgyarto, Koen D. Flach, Mark Opdam, Carlo Palmieri, Sabine C. Linn, Jelle Wesseling, Simak Ali, Judith M. Bliss, Maggie Chon U. Cheang, Wilbert Zwart, R. Charles Coombes
Microchipping the breast: an effective new technology for localizing non-palpable breast lesions for surgery
Maggie L. DiNome, Amy M. Kusske, Deanna J. Attai, Cheryce P. Fischer, Anne C. Hoyt
The effects of psychosexual counseling on sexual quality of life and function in Iranian breast cancer survivors: a randomized controlled trial
Shakiba Fatehi, Raziyeh Maasoumi, Giti Atashsokhan, Azam Hamidzadeh, Ghasem Janbabaei, Seyed Mohammad Mirrezaie
Factors influencing the use of extended adjuvant endocrine therapy
Kunal C. Kadakia, Kelley M. Kidwell, Debra L. Barton, Anne F. Schott, Daniel F. Hayes, Jennifer J. Griggs, N. Lynn Henry
Efficacy of self-administered complex decongestive therapy on breast cancer-related lymphedema: a single-blind randomized controlled trial
M. B. Ligabue, I. Campanini, P. Veroni, A. Cepelli, M. Lusuardi, A. Merlo
Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort
Jiwoong Jung, Wonshik Han, Eun Sook Lee, So-Youn Jung, Jai Hong Han, Dong-Young Noh, Yumi Kim, Hee Jun Choi, Jeong Eon Lee, Seok Jin Nam, Jong Won Lee, Hee Jeong Kim, Eunhae Um, Joo Heung Kim, Seho Park, Young Up Cho
High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer
Ulrich Bick, Christoph Engel, Barbara Krug, Walter Heindel, Eva M. Fallenberg, Kerstin Rhiem, David Maintz, Michael Golatta, Dorothee Speiser, Dorothea Rjosk-Dendorfer, Irina Lämmer-Skarke, Frederic Dietzel, Karl Werner Fritz Schäfer, Elena Leinert, Stefanie Weigel, Stephanie Sauer, Stefanie Pertschy, Thomas Hofmockel, Anne Hagert-Winkler, Karin Kast, Anne Quante, Alfons Meindl, Marion Kiechle, Markus Loeffler, Rita K. Schmutzler, Jens-Uwe Blohmer, Denise Horn, Raymonda Varon-Mateeva, Verena Hübbel, Natalie Herold, Michael Püsken, Pauline Wimberger, Cornelia Meisel, Katja Keller, Gerald Antoch, Anne-Sophie Vesper, Tanja N. Fehm, Brigitte Schlegelberger, Bernd Auber, Hannah Wallaschek, Jörg Heil, Sarah Schott, Nicola Dikow, Christoph Mundhenke, Norbert Arnold, Almuth Caliebe, Susanne Briest, Johannes Lemke, Sabine Gril, Katharina Pfeifer, Juliane Ramser, Sven Mahner, Nina Ditsch, Christine Zeder-Göß, Joke Tio, Matthias Burg, Judith Horvath, Reiner Siebert, Jasmin Bartholomä, Wolfgang Janni, Thorsten Bley, Achim Wöckel, Thomas Haaf, Silke Zachariae, Karolin Bucksch, Ute Enders
Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at risk
Anna Weiss, Samantha Grossmith, Danielle Cutts, Sage A. Mikami, Johanna A. Suskin, Mary Knust Graichen, Negui Arilis Rojas, Lydia E. Pace, Eileen Joyce, Esther Rhei, Rochelle Scheib, Brittany Bychkovsky, Judy E. Garber, Daniel Morganstern, Tari A. King
Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction
Yasin Hussain, Esther Drill, Chau T. Dang, Jennifer E. Liu, Richard M. Steingart, Anthony F. Yu
Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women
Tess O’Meara, Anton Safonov, David Casadevall, Tao Qing, Andrea Silber, Brigid Killelea, Christos Hatzis, Lajos Pusztai
HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment
Kadri Altundag
Change in study randomization allocation needs to be included in statistical analysis: comment on ‘Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study’
Stephanie L. Dickinson, Lilian Golzarri-Arroyo, Andrew W. Brown, Bryan McComb, Chanaka N. Kahathuduwa, David B. Allison
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
Ulrike Nitz, Oleg Gluz, Matthias Christgen, Ronald E. Kates, Michael Clemens, Wolfram Malter, Benno Nuding, Bahriye Aktas, Sherko Kuemmel, Toralf Reimer, Andrea Stefek, Fatemeh Lorenz-Salehi, Petra Krabisch, Marianne Just, Doris Augustin, Cornelia Liedtke, Calvin Chao, Steven Shak, Rachel Wuerstlein, Hans H. Kreipe, Nadia Harbeck